Search Results - Attilio Olivieri

Refine Results
  1. 1
    Dasatinib: a new step in molecular target therapy

    Dasatinib: a new step in molecular target therapy by Attilio Olivieri, Luigi Manzione

    Published 2007
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD

    Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD by Attilio Olivieri, Giorgia Mancini

    Published 2024
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

    Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety by Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    The Time Has Come for Targeted Therapies for AML: Lights and Shadows

    The Time Has Come for Targeted Therapies for AML: Lights and Shadows by Alessandro Fiorentini, Debora Capelli, Francesco Saraceni, Diego Menotti, Antonella Poloni, Attilio Olivieri

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments by Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo

    Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo by Attilio Olivieri, Monia Marchetti, Roberto M. Lemoli, Corrado Tarella, A Iacone, Francesco Lanza, Alessandro Rambaldi, Alberto Bosi

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Molecular and functional characterization of human bone marrow adipocytes

    Molecular and functional characterization of human bone marrow adipocytes by Antonella Poloni, Giulia Maurizi, Federica Serrani, Stefania Mancini, Maria Cristina Zingaretti, Andrea Frontini, Saverio Cinti, Attilio Olivieri, Pietro Leoni

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2

    The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2 by Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, Giancarlo Discepoli, Sonia Liberati, Attilio Olivieri, Matteo Santoni, Giorgio Santoni, Pietro Leoni, Massimo Nabissi

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease

    Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease by Silvia Svegliati, Attilio Olivieri, Nadia Campelli, Michele Maria Luchetti, Antonella Poloni, Silvia Trappolini, Gianluca Moroncini, Andrea Bacigalupo, Pietro Leoni, Enrico V. Avvedimento, Armando Gabrielli

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway

    Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway by Elena Marinelli Busilacchi, Andrea Costantini, Giorgia Mancini, Giovanni Tossetta, Jacopo Olivieri, Antonella Poloni, Nadia Viola, Luca Butini, Anna Campanati, Gaia Goteri, Daniela Marzioni, Attilio Olivieri

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation

    Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation by Jacopo Mariotti, Francesco Maura, Francesco Spina, Luisa Roncari, Anna Dodero, Lucia Farina, Vittorio Montefusco, Cristiana Carniti, Barbara Sarina, Francesca Patriarca, Alessandro Rambaldi, Francesco Onida, Attilio Olivieri, Francesco Zallio, Paolo Corradini

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group

    A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operativ... by Gino Santini, Cármino Antônio De Souza, Savina Aversa, Caterina Patti, L. Tedeschi, Marco Candela, Attilio Olivieri, Teodoro Chisesi, A. Rubagotti, Riccardo Centurioni, Valentina Nardi, M. Congiu, Massimiliano Gennaro, Mauro Truini

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma

    Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma by Immacolata Attolico, Vincenzo Pavone, Angelo Ostuni, Bernardo Rossini, Maurizio Musso, Alessandra Crescimanno, Massimo Martino, Pasquale Iacopino, Giuseppe Milone, Patrizia Tedeschi, Sabrina Coluzzi, Roberta Nuccorini, Sara Pasquina Pascale, Elvira Di Nardo, Attilio Olivieri

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA

    Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA by Attilio Olivieri, Guido Gini, Caterina Bocci, Mauro Montanari, Silvia Trappolini, Jacopo Olivieri, Marino Brunori, Massimo Catarini, Barbara Guiducci, Alessandro Isidori, Francesco Alesiani, Luciano Giuliodori, Massimo Marcellini, Giuseppe Visani, Antonella Poloni, Pietro Leoni

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

    A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study by Patrizia Chiusolo, Gesine Bug, Attilio Olivieri, Mats Brune, Nicola Mordini, P Alessandrino, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Francesca Gualandi, Maria Teresa Van Lint, Felicetto Ferrara, Olimpia Finizio, Emanuele Angelucci, Andrea Bacigalupo

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Factors affecting successful mobilization with plerixafor: an <scp>I</scp>talian prospective survey in 215 patients with multiple myeloma and lymphoma

    Factors affecting successful mobilization with plerixafor: an <scp>I</scp>talian prospective survey in 215 patients with multiple myeloma and lymphoma by Francesco Lanza, Roberto M. Lemoli, Attilio Olivieri, Daniele Laszlò, Massimo Martino, Giorgina Specchia, Vincenzo Pavone, Manuela Imola, Annalisa Pasini, Giuseppe Milone, Ilaria Scortechini, Elisabetta Todisco, Elena Guggiari, Nicola Cascavilla, Giovanni Martinelli, Alessandro Rambaldi, Alberto Bosi

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

    Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy... by Nicola Di Renzo, Antonella Montanini, Donato Mannina, Alessandra Dondi, Stefania Muci, Salvatrice Mancuso, Maria Rosaria De Paolis, Caterina Plati, Caterina Stelitano, C. de L. Patti, Attilio Olivieri, Eliana Valentina Liardo, Gabriele Buda, Renato Cantaffa, Massimo Federico

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Treatment of refractory chronic GVHD with rituximab: a GITMO study

    Treatment of refractory chronic GVHD with rituximab: a GITMO study by Francesco Zaja, Andrea Bacigalupo, Francesca Patriarca, Marta Stanzani, Maria Teresa Van Lint, C. Filì, Rosanna Scimè, Giuseppe Milone, Michele Falda, Claudia Vener, Daniele Laszlò, P Alessandrino, Franco Narni, Simona Sica, Attilio Olivieri, Alessandra Sperotto, Alberto Bosi, Francesca Bonifazi, Renato Fanin

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG

    Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG by Attilio Olivieri, Gino Santini, Caterina Patti, Teodoro Chisesi, Cármino Antônio De Souza, A. Rubagotti, Savina Aversa, Atto Billio, Antonio Porcellini, Marco Candela, Riccardo Centurioni, A Congiu, Marino Brunori, S Nati, Mauro Spriano, R. Vimercati, Gloria E. Marino, A. Contu, L. Tedeschi, Ignazio Majolino, Monica Crugnola, M.R. Sertoli

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

    Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-ve... by Stephanie J. Lee, Daniel Wolff, Carrie L. Kitko, John Koreth, Yoshihiro Inamoto, Madan Jagasia, Joseph Pidala, Attilio Olivieri, Paul J. Martin, Donna Przepiorka, Iskra Pusic, Fiona L. Dignan, Sandra A. Mitchell, Ánita Lawitschka, David A. Jacobsohn, Anne M. Hall, Mary E.D. Flowers, Kirk R. Schultz, Georgia B. Vogelsang, Steven Z. Pavletic

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: